These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

344 related items for PubMed ID: 1776861

  • 1. Adjuvant hormone treatment and chemotherapy in postmenopausal women with operable breast cancer: a retrospective analysis.
    Oriana S, Coradini D, Sasso GM, Di Fronzo G.
    Anticancer Res; 1991; 11(6):2199-205. PubMed ID: 1776861
    [Abstract] [Full Text] [Related]

  • 2. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
    Gasparini G, Barbareschi M, Doglioni C, Palma PD, Mauri FA, Boracchi P, Bevilacqua P, Caffo O, Morelli L, Verderio P.
    Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
    [Abstract] [Full Text] [Related]

  • 3. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.
    Lin YC, Chen SC, Chang HK, Hsueh S, Tsai CS, Lo YF, Hwang TL, Chen MF.
    Jpn J Clin Oncol; 2005 Sep; 35(9):514-9. PubMed ID: 16199422
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Adjuvant treatment for early breast cancer: the Ludwig breast cancer studies.
    Goldhirsch A, Gelber R.
    NCI Monogr; 1986 Sep; (1):55-70. PubMed ID: 3774016
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102.
    Hutchins LF, Green SJ, Ravdin PM, Lew D, Martino S, Abeloff M, Lyss AP, Allred C, Rivkin SE, Osborne CK.
    J Clin Oncol; 2005 Nov 20; 23(33):8313-21. PubMed ID: 16293862
    [Abstract] [Full Text] [Related]

  • 10. Thirty-year follow-up of chemo/hormonal therapy in node-positive breast cancer.
    Gordon NH, Silverman P, Lasheen W, Meinert J, Siminoff LA.
    Breast Cancer Res Treat; 2007 May 20; 102(3):301-12. PubMed ID: 17033926
    [Abstract] [Full Text] [Related]

  • 11. Chemotherapy versus observation in high-risk node-negative breast cancer patients.
    Mansour EG, Eudey L, Tormey DC, Shatila AH, Osborne CK, Gilchrist KW, Cooper MR, Falkson G.
    J Natl Cancer Inst Monogr; 1992 May 20; (11):97-104. PubMed ID: 1627437
    [Abstract] [Full Text] [Related]

  • 12. Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate).
    Schmid P, Untch M, Wallwiener D, Kossé V, Bondar G, Vassiljev L, Tarutinov V, Kienle E, Lüftner D, Possinger K, TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate).
    Anticancer Res; 2002 May 20; 22(4):2325-32. PubMed ID: 12174922
    [Abstract] [Full Text] [Related]

  • 13. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M, Rodríguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, Munárriz B, Rodríguez CA, Crespo C, de Alava E, López García-Asenjo JA, Guitián MD, Almenar S, González-Palacios JF, Vera F, Palacios J, Ramos M, Gracia Marco JM, Lluch A, Alvarez I, Seguí MA, Mayordomo JI, Antón A, Baena JM, Plazaola A, Modolell A, Pelegrí A, Mel JR, Aranda E, Adrover E, Alvarez JV, García Puche JL, Sánchez-Rovira P, Gonzalez S, López-Vega JM, GEICAM 9906 Study Investigators.
    J Natl Cancer Inst; 2008 Jun 04; 100(11):805-14. PubMed ID: 18505968
    [Abstract] [Full Text] [Related]

  • 14. Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF.
    Poikonen P, Saarto T, Lundin J, Joensuu H, Blomqvist C.
    Br J Cancer; 1999 Aug 04; 80(11):1763-6. PubMed ID: 10468293
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.
    BMC Cancer; 2007 Apr 12; 7():63. PubMed ID: 17430582
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17.
    Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL, National Cancer Institute of Canada Clinical Trials Group MA.17.
    J Clin Oncol; 2007 May 20; 25(15):2006-11. PubMed ID: 17452676
    [Abstract] [Full Text] [Related]

  • 18. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18.
    Fisher ER, Wang J, Bryant J, Fisher B, Mamounas E, Wolmark N.
    Cancer; 2002 Aug 15; 95(4):681-95. PubMed ID: 12209710
    [Abstract] [Full Text] [Related]

  • 19. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.
    International Breast Cancer Study GroupDivision of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy. marco.colleoni@ieo.it, Colleoni M, Gelber S, Goldhirsch A, Aebi S, Castiglione-Gertsch M, Price KN, Coates AS, Gelber RD.
    J Clin Oncol; 2006 Mar 20; 24(9):1332-41. PubMed ID: 16505417
    [Abstract] [Full Text] [Related]

  • 20. Adjuvant tamoxifen versus tamoxifen plus CMF in the treatment of early breast cancer in Greece. Fifteen-year results of a randomised prospective trial and the potential risks of the antioestrogen.
    Vorgias G, Koukouras D, Tzoracoeleftherakis E, Paleogianni V, Androulakis J.
    Anticancer Res; 2000 Mar 20; 20(5C):3849-54. PubMed ID: 11268466
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.